vs
Orion Group Holdings Inc（ORN）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
Orion Group Holdings Inc的季度营收约是再鼎医药的1.7倍（$216.3M vs $127.1M），再鼎医药同比增速更快（17.1% vs 14.6%），过去两年再鼎医药的营收复合增速更高（20.8% vs 6.1%）
奥里昂集团是源自芬兰的全球化制药企业，1917年成立，总部位于芬兰埃斯波。公司面向全球市场研发、生产并销售人用与兽用药品以及药用活性成分，旗下全部生产基地与大部分研发部门均设立在芬兰。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
ORN vs ZLAB — 直观对比
营收规模更大
ORN
是对方的1.7倍
$127.1M
营收增速更快
ZLAB
高出2.5%
14.6%
两年增速更快
ZLAB
近两年复合增速
6.1%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $216.3M | $127.1M |
| 净利润 | $4.7M | — |
| 毛利率 | 12.0% | 51.0% |
| 营业利润率 | — | -54.6% |
| 净利率 | 2.2% | — |
| 营收同比 | 14.6% | 17.1% |
| 净利润同比 | 435.7% | — |
| 每股收益（稀释后） | $0.12 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ORNZLAB
| Q1 26 | $216.3M | — | ||
| Q4 25 | $233.2M | $127.1M | ||
| Q3 25 | $225.1M | $115.4M | ||
| Q2 25 | $205.3M | $109.1M | ||
| Q1 25 | $188.7M | $105.7M | ||
| Q4 24 | $216.9M | $108.5M | ||
| Q3 24 | $226.7M | $101.8M | ||
| Q2 24 | $192.2M | $100.1M |
净利润ORNZLAB
| Q1 26 | $4.7M | — | ||
| Q4 25 | $-240.0K | — | ||
| Q3 25 | $3.3M | $-36.0M | ||
| Q2 25 | $841.0K | $-40.7M | ||
| Q1 25 | $-1.4M | $-48.4M | ||
| Q4 24 | $6.8M | — | ||
| Q3 24 | $4.3M | $-41.7M | ||
| Q2 24 | $-6.6M | $-80.3M |
毛利率ORNZLAB
| Q1 26 | 12.0% | — | ||
| Q4 25 | 11.6% | 51.0% | ||
| Q3 25 | 13.2% | 59.5% | ||
| Q2 25 | 12.6% | 60.6% | ||
| Q1 25 | 12.2% | 63.6% | ||
| Q4 24 | 14.0% | 61.5% | ||
| Q3 24 | 11.9% | 64.1% | ||
| Q2 24 | 9.5% | 64.9% |
营业利润率ORNZLAB
| Q1 26 | — | — | ||
| Q4 25 | 2.2% | -54.6% | ||
| Q3 25 | 2.4% | -42.3% | ||
| Q2 25 | 1.7% | -50.3% | ||
| Q1 25 | 0.4% | -53.3% | ||
| Q4 24 | 4.4% | -62.6% | ||
| Q3 24 | 3.4% | -66.6% | ||
| Q2 24 | -1.4% | -76.0% |
净利率ORNZLAB
| Q1 26 | 2.2% | — | ||
| Q4 25 | -0.1% | — | ||
| Q3 25 | 1.5% | -31.2% | ||
| Q2 25 | 0.4% | -37.3% | ||
| Q1 25 | -0.7% | -45.8% | ||
| Q4 24 | 3.1% | — | ||
| Q3 24 | 1.9% | -40.9% | ||
| Q2 24 | -3.4% | -80.2% |
每股收益（稀释后）ORNZLAB
| Q1 26 | $0.12 | — | ||
| Q4 25 | $-0.00 | $-0.05 | ||
| Q3 25 | $0.08 | $-0.03 | ||
| Q2 25 | $0.02 | $-0.04 | ||
| Q1 25 | $-0.04 | $-0.04 | ||
| Q4 24 | $0.22 | $-0.09 | ||
| Q3 24 | $0.12 | $-0.04 | ||
| Q2 24 | $-0.20 | $-0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $6.3M | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $166.7M | $715.5M |
| 总资产 | $478.7M | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ORNZLAB
| Q1 26 | $6.3M | — | ||
| Q4 25 | $1.6M | $689.6M | ||
| Q3 25 | $4.9M | $717.2M | ||
| Q2 25 | $1.7M | $732.2M | ||
| Q1 25 | $13.0M | $757.3M | ||
| Q4 24 | $28.3M | $779.7M | ||
| Q3 24 | $28.3M | $616.1M | ||
| Q2 24 | $4.8M | $630.0M |
总债务ORNZLAB
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $33.4M | — | ||
| Q1 25 | $23.3M | — | ||
| Q4 24 | $23.2M | — | ||
| Q3 24 | $28.0M | — | ||
| Q2 24 | $60.3M | — |
股东权益ORNZLAB
| Q1 26 | $166.7M | — | ||
| Q4 25 | $159.0M | $715.5M | ||
| Q3 25 | $157.9M | $759.9M | ||
| Q2 25 | $153.2M | $791.7M | ||
| Q1 25 | $150.8M | $810.8M | ||
| Q4 24 | $150.7M | $840.9M | ||
| Q3 24 | $142.4M | $667.7M | ||
| Q2 24 | $111.1M | $704.2M |
总资产ORNZLAB
| Q1 26 | $478.7M | — | ||
| Q4 25 | $414.7M | $1.2B | ||
| Q3 25 | $422.4M | $1.2B | ||
| Q2 25 | $432.7M | $1.2B | ||
| Q1 25 | $416.3M | $1.2B | ||
| Q4 24 | $417.3M | $1.2B | ||
| Q3 24 | $430.3M | $985.3M | ||
| Q2 24 | $414.0M | $987.4M |
负债/权益比ORNZLAB
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.22× | — | ||
| Q1 25 | 0.15× | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.20× | — | ||
| Q2 24 | 0.54× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | — | $-26.7M |
| 自由现金流率自由现金流/营收 | — | -21.0% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-158.9M |
8季度趋势，按日历期对齐
经营现金流ORNZLAB
| Q1 26 | — | — | ||
| Q4 25 | $13.8M | $-26.0M | ||
| Q3 25 | $23.3M | $-32.0M | ||
| Q2 25 | $-5.6M | $-31.0M | ||
| Q1 25 | $-3.4M | $-61.7M | ||
| Q4 24 | $13.4M | $-55.8M | ||
| Q3 24 | $37.5M | $-26.8M | ||
| Q2 24 | $-15.3M | $-42.2M |
自由现金流ORNZLAB
| Q1 26 | — | — | ||
| Q4 25 | $454.0K | $-26.7M | ||
| Q3 25 | $13.9M | $-35.0M | ||
| Q2 25 | $-12.7M | $-33.9M | ||
| Q1 25 | $-12.5M | $-63.2M | ||
| Q4 24 | $9.9M | $-58.4M | ||
| Q3 24 | $33.3M | $-28.2M | ||
| Q2 24 | $-20.0M | $-42.9M |
自由现金流率ORNZLAB
| Q1 26 | — | — | ||
| Q4 25 | 0.2% | -21.0% | ||
| Q3 25 | 6.2% | -30.4% | ||
| Q2 25 | -6.2% | -31.1% | ||
| Q1 25 | -6.6% | -59.9% | ||
| Q4 24 | 4.6% | -53.8% | ||
| Q3 24 | 14.7% | -27.7% | ||
| Q2 24 | -10.4% | -42.9% |
资本支出强度ORNZLAB
| Q1 26 | — | — | ||
| Q4 25 | 5.7% | 0.5% | ||
| Q3 25 | 4.2% | 2.6% | ||
| Q2 25 | 3.5% | 2.6% | ||
| Q1 25 | 4.8% | 1.5% | ||
| Q4 24 | 1.6% | 2.4% | ||
| Q3 24 | 1.8% | 1.3% | ||
| Q2 24 | 2.4% | 0.7% |
现金转化率ORNZLAB
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 7.05× | — | ||
| Q2 25 | -6.61× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.98× | — | ||
| Q3 24 | 8.79× | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ORN
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
